Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Fox

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 7, 2022
Insights into the management of patients with primary central nervous system lymphomaChristopher P Fox
Blood|March 2, 2019
Refining CNS relapse risk in DLBCL: easy as ABC?Christopher P Fox
The Journal of Infectious Diseases|October 27, 2012
Epstein-Barr virus and infectious mononucleosis: what students can teach usAlan B Rickinson, Christopher P Fox
Blood|February 6, 2010
EBV meets its matchChristopher P Fox, Alan B Rickinson
Herpesviridae|September 9, 2011
Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferationsChristopher P Fox, Claire Shannon-Lowe, Martin Rowe
Annals of Lymphoma|March 7, 2022
Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practicePrakash Ambady, Nancy D Doolittle, Christopher P Fox
Current Hematologic Malignancy Reports|June 28, 2014
Primary CNS lymphomaElizabeth H Phillips, Christopher P Fox, Kate Cwynarski
Current Hematologic Malignancy Reports|September 18, 2012
Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolvedLindsay C George, Martin Rowe, Christopher P Fox
British Journal of Haematology|May 6, 2016
The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naΪve patients with peripheral T-cell lymphoma: a systematic review of the literatureKetan D Jethwa, Mark J Bishton, Christopher P Fox
British Journal of Haematology|March 29, 2016
Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and KweeMark J Bishton, Andrew K McMillan, Christopher P Fox
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Clinical Advances in Hematology & Oncology : H&O|April 7, 2022
Insights into the management of patients with primary central nervous system lymphomaChristopher P Fox
Blood|March 2, 2019
Refining CNS relapse risk in DLBCL: easy as ABC?Christopher P Fox
The Journal of Infectious Diseases|October 27, 2012
Epstein-Barr virus and infectious mononucleosis: what students can teach usAlan B Rickinson, Christopher P Fox
Blood|February 6, 2010
EBV meets its matchChristopher P Fox, Alan B Rickinson
Herpesviridae|September 9, 2011
Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferationsChristopher P Fox, Claire Shannon-Lowe, Martin Rowe
Annals of Lymphoma|March 7, 2022
Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practicePrakash Ambady, Nancy D Doolittle, Christopher P Fox
Current Hematologic Malignancy Reports|June 28, 2014
Primary CNS lymphomaElizabeth H Phillips, Christopher P Fox, Kate Cwynarski
Current Hematologic Malignancy Reports|September 18, 2012
Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolvedLindsay C George, Martin Rowe, Christopher P Fox
British Journal of Haematology|May 6, 2016
The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naΪve patients with peripheral T-cell lymphoma: a systematic review of the literatureKetan D Jethwa, Mark J Bishton, Christopher P Fox
British Journal of Haematology|March 29, 2016
Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and KweeMark J Bishton, Andrew K McMillan, Christopher P Fox
Pageof 13